Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 14/20 | 0.59 |
| ▸ | F13A1 | P00488 | 3/20 | 0.59 |
| ▸ | TGM1 | P22735 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.59 |
| ▸ | THRA | P10827 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.48 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL440756 | 0.85 | TGM2 (0.63) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL439369 | 0.84 | TGM2 (0.79) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL16242100 | 0.83 | TGM2 (0.61) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL1191835 | 0.83 | TGM2 (0.61) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL25293287 | 0.81 | TGM2 (0.59) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL16653882 | 0.81 | TGM2 (0.59) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL1132464 | 0.81 | THRA (0.67) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL6279031 | 0.81 | TGM2 (0.59) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL31325510 | 0.81 | TGM2 (0.65) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL8867209 | 0.80 | THRA (0.65) | TGM2F13A1TGM1LMNATGM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102625708-A | Pi3 kinase inhibitors and uses thereof | AVILA THERAPEUTICS INC | 2012-08-01 | — | — | CN | disclosed |
| EP-2475375-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| WO-2011031896-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| US-4396698-A | CROSSLINKED CATIONIC ADDITION COPOLYMERS AND HYDROPHOBIC PHENOLIC-TYPE COMPOUNDS; LIGHT SENSITIVE ELEMENTS | FUJI PHOTO FILM CO., LTD. (JP) | 1983-08-02 | — | — | US | disclosed |
| US-4193800-A | COLOR DIFFUSION TRANSFER, POLYMER HAVING ACRYLOLAMINOPHENYL AMMONIUM UNITS | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1980-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | TGM2 2927/4885F13A1 3853/4885TGM1 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.